IP Library Granted Patent US 9,765,129
Granted Patent B2
US 9,765,129 · App. 13/968,977 · Granted Sep 19, 2017

Treatment of obesity

Inventors: Mark Anthony Febbraio (Lower Plenty, AU); Stefan Rose-John (Schellhorn, DE)
Assignees: Baker Medical Research Institute; Christian-Albrechts-Universität zu Kiel
C07K14/5412C07K14/475C07K14/48A61K38/00C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,765,129
App. No.
13/968,977
Granted
Sep 19, 2017
Kind
B2
Abstract

The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.

Claims (3)

1. A method for increasing fat oxidation wherein the method comprises administering to the mammal a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 7, which amino acid sequence corresponds to the amino acid sequence of an IL-6/CNTF chimeric polypeptide in which the site III loop of the CNTF replaces the site III loop of IL-6 and which comprises an IL-6 receptor binding site, a gp130 binding site and a LIF receptor binding site that permit the polypeptide to bind the IL-6 receptor and to signal via a gp130/LIF receptor heterodimer.

2. The method according to claim 1 , wherein the mammal is obese and has a condition selected from the group consisting of osteoarthritis, type II diabetes mellitus, hypertension, stroke, and cardiovascular disease.

3. The method of claim 1 , wherein the mammal is a human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2014
From: FEBBRAIO, MARK ANTHONY; ROSE-JOHN, STEFAN
To: BAKER MEDICAL RESEARCH INSTITUTE; CHRISTIAN-ALBRECHTS-UNIVERSITAT ZU KIEL
Reel/Frame 032110/0694 →
Continuity (3)
Division 12593708
Provisional Application 60920822 · Mar 30, 2007
Related Publication 20140140949A1 · May 22, 2014